Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
244 studies found for:    scleroderma
Show Display Options
Rank Status Study
21 Recruiting Gastroesophageal Reflux Treatment in Scleroderma
Conditions: Gastroesophageal Reflux Disease;   Systemic Sclerosis;   Scleroderma
Interventions: Drug: Alginic acid;   Drug: placebo (for domperidone);   Drug: Domperidone;   Drug: placebo (of alginic acid)
22 Completed Effectiveness and Safety of Lidocaine for Scleroderma
Condition: Scleroderma
Interventions: Drug: Lidocaine 2% without vessel constrictor;   Other: Placebo - physiological solution 0,9%
23 Recruiting Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Conditions: Scleroderma, Localized;   Morphea;   Frontal Linear Scleroderma en Coup de Sabre;   Scleroderma, Circumscribed;   Scleroderma, Linear
Intervention: Other: Morphea
24 Not yet recruiting Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Interventions: Other: Probiotic;   Other: Placebo
25 Unknown  High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Intervention: Drug: N-acetylcysteine (NAC)
26 Enrolling by invitation Lower Urinary Tract Symptoms in Systemic Sclerosis
Conditions: Urinary Symptoms;   Systemic Sclerosis
Intervention:
27 Completed
Has Results
High Dose Cyclophosphamide for Treatment of Scleroderma
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide
28 Recruiting Neuropsychiatric Scleroderma Study: Systematic Evaluation of Neuropsychiatric Involvement in Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Other: Magnetic resonance Imaging
29 Unknown  SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
Conditions: Scleroderma, Systemic;   Sclerosis
Intervention: Behavioral: Telephone Call
30 Recruiting Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Conditions: Systemic Sclerosis;   Scleroderma;   Pulmonary Hypertension;   Pulmonary Arterial Hypertension
Intervention:
31 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
32 Recruiting Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Condition: Scleroderma Lung
Intervention:
33 Active, not recruiting Scleroderma: Cyclophosphamide or Transplantation (SCOT)
Conditions: Scleroderma, Systemic;   Sclerosis;   Autoimmune Disease
Interventions: Procedure: Autologous stem cell transplantation;   Drug: Cyclophosphamide;   Drug: Antithymocyte globulin, equine;   Drug: Methylprednisolone;   Drug: Growth colony stimulating factor (G-CSF);   Radiation: Total body irradiation (TBI)
34 Terminated
Has Results
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Conditions: Systemic Scleroderma;   Pulmonary Hypertension
Interventions: Drug: Bosentan;   Drug: Placebo
35 Terminated Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Conditions: Scleroderma;   Systemic Sclerosis
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thymoglobulin;   Procedure: Leukapheresis;   Procedure: Self bone marrow transplant
36 Completed Premature Coronary Atherosclerosis in Scleroderma
Condition: Scleroderma
Intervention:
37 Recruiting Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
Conditions: SYSTEMIC SCLERODERMA;   ALLOGENEIC MESENCHYMAL STEM CELLS;   ADULT
Intervention: Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS
38 Completed A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Conditions: Scleroderma, Diffuse;   Scleroderma, Systemic
Intervention: Drug: Abatacept
39 Completed Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Scleroderma Patients
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Bosentan
40 Unknown  Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan with an anti-fibrotic agent to assess benefit on skin.

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years